Advocacy | ASGCT - American Society of Gene & Cell Therapy | ASGCT

Policy Issues

Policy Priorities

Learn about the Policy & Advocacy team's areas of focus, pipeline indications in the next five years, and more.

Research Funding

Through congressional advocacy, including one-on-one meetings with legislative staff, briefings, and letters, ASGCT advocates for federal funding for gene and cell therapy research.

Regulatory Policy

ASGCT advocates for a predictable and efficient regulatory environment that supports safe and effective clinical translation of gene and cell therapies.

Responsible Use of Technology

ASGCT has made it a priority to support dialogue and exchange of ideas as new gene and cell therapy technologies prompt new questions about their use.

ASGCT–FDA Liaison Meeting

ASGCT meets annually with FDA staff in the Office of Tissues and Advanced Therapies (OTAT) to share new developments, highlight ongoing challenges, and recommend solutions for the CGT field.

Patient Access Priorities

Patient Access Overview

Since the surge in gene and cell therapy approvals and development, ASGCT has advocated for policies that support patient access to these products in a variety of ways.

Learn More

To obtain access to, and maximal benefit from, potentially life-altering approved gene therapies, diagnosing patients as early as possible is critical. ASGCT advocates to federal policymakers to support access to genetic testing and screening.

Payment Policy

ASGCT supports payment policies that facilitate patient access to approved gene and cell therapies, including full coverage of FDA-labeled indications, maximal reimbursement of providers, and the use of innovative payment mechanisms.

Clinical Trials Finder

A resource for patients and professionals in the field, our finder identifies gene and cell therapy clinical trials globally.

Class Considerations on Immunogenicity for AAV GT Products

January 22-23, 2025 | Virtual

ASGCT Policy Statements + Letters